Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in ATTR-CA Post Heart Transplantation
NCT05489523Phase 4Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by UT Southwestern Medical Center. Started May 2023; status: active, not recruiting.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT05489523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489523.